Renovis Cuts Workforce By 40 Percent To Focus On Preclinical Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
Eliminations follow Phase III failure of an acute ischemic stroke candidate that had been in development with AstraZeneca.
You may also be interested in...
Evotec Acquires Renovis In $152 Million Deal
Agreement will create company with six preclinical and clinical candidates for a broad range of central nervous system applications.
Evotec Acquires Renovis In $152 Million Deal
Agreement will create company with six preclinical and clinical candidates for a broad range of central nervous system applications.
Renovis Gains Funding From Pfizer To Further VR1 Receptor Research
Extension of existing collaboration with Pfizer will fund Renovis’ research in the area through June 30, 2008.